Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing ...
The 100% remission rate (CR/CRi) achieved at the highest dose level of the RAINIER trial to date demonstrates mipletamig's potential to redefine the frontline treatment landscape for newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback